NCT00062478 2020-03-12
Study of Karenitecin (BNP1350) in Patients With Brain Tumors
BioNumerik Pharmaceuticals, Inc.
Phase 2 Completed
Clinical Trials
8 trialsNCT00062491 2020-03-12
Study of Karenitecin (BNP1350) to Treat Malignant Melanoma
BioNumerik Pharmaceuticals, Inc.
Phase 2 Completed
NCT00097903 2020-03-12
Trial of Oral Karenitecin in Patients With Solid Tumors and Lung Cancer
BioNumerik Pharmaceuticals, Inc.
Phase 1 Completed
NCT00477282 2020-03-12
Karenitecin Versus Topotecan in Patients With Advanced Epithelial Ovarian Cancer
BioNumerik Pharmaceuticals, Inc.
Phase 3 Completed
NCT00054119 2017-07-13
Karenitecin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer
GOG Foundation
Phase 2 Completed
NCT00010218 2016-07-19
Karenitecin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00358319 2013-11-25
Phase I/II Trial of Valproic Acid and Karenitecin for Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Terminated
NCT00014521 2008-07-24
Karenitecin in Treating Patients With Recurrent Malignant Glioma
National Cancer Institute (NCI)
Phase 1 Completed